Logo image of ELABS.OL

ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

OSL:ELABS - Euronext Oslo - NO0010722283 - Common Stock - Currency: NOK

11.14  -0.16 (-1.42%)

Fundamental Rating

3

Overall ELABS gets a fundamental rating of 3 out of 10. We evaluated ELABS against 101 industry peers in the Software industry. The financial health of ELABS is average, but there are quite some concerns on its profitability. ELABS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ELABS had negative earnings in the past year.
ELABS had a negative operating cash flow in the past year.
ELABS had negative earnings in each of the past 5 years.
ELABS had a negative operating cash flow in each of the past 5 years.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ELABS's Return On Assets of -6.37% is on the low side compared to the rest of the industry. ELABS is outperformed by 69.31% of its industry peers.
With a Return On Equity value of -7.05%, ELABS is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -6.37%
ROE -7.05%
ROIC N/A
ROA(3y)-7.78%
ROA(5y)-7.71%
ROE(3y)-8.59%
ROE(5y)-9.8%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

ELABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

ELABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ELABS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ELABS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ELABS has a better Debt to Equity ratio (0.04) than 84.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.48%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

ELABS has a Current Ratio of 8.41. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.41, ELABS belongs to the top of the industry, outperforming 97.03% of the companies in the same industry.
ELABS has a Quick Ratio of 8.41. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
ELABS's Quick ratio of 8.41 is amongst the best of the industry. ELABS outperforms 97.03% of its industry peers.
Industry RankSector Rank
Current Ratio 8.41
Quick Ratio 8.41
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.67% over the past year.
EPS 1Y (TTM)91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%19.73%

3.2 Future

Based on estimates for the next years, ELABS will show a very strong growth in Earnings Per Share. The EPS will grow by 195.30% on average per year.
ELABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 62.13% yearly.
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A

3.3 Evolution

ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELABS. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 8.32 indicates a reasonable valuation of ELABS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ELABS indicates a rather cheap valuation: ELABS is cheaper than 96.04% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, ELABS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.32
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ELABS's earnings are expected to grow with 195.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y309.11%
EPS Next 3Y195.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELABS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELLIPTIC LABORATORIES ASA

OSL:ELABS (5/30/2025, 7:00:00 PM)

11.14

-0.16 (-1.42%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-22 2025-05-22/bmo
Earnings (Next)N/A N/A
Inst Owners35.91%
Inst Owner ChangeN/A
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap1.17B
Analysts84.44
Price Target19.38 (73.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.25%
Min Revenue beat(2)-19.76%
Max Revenue beat(2)-12.73%
Revenue beat(4)0
Avg Revenue beat(4)-29.61%
Min Revenue beat(4)-79.79%
Max Revenue beat(4)-6.15%
Revenue beat(8)1
Avg Revenue beat(8)-27.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.32
P/S 12.53
P/FCF N/A
P/OCF N/A
P/B 3.73
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)1.34
Fwd EY12.02%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.89
BVpS2.99
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.37%
ROE -7.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.78%
ROA(5y)-7.71%
ROE(3y)-8.59%
ROE(5y)-9.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.16%
Cap/Sales 32.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.41
Quick Ratio 8.41
Altman-Z N/A
F-Score4
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)191.96%
Cap/Depr(5y)213.4%
Cap/Sales(3y)38.18%
Cap/Sales(5y)37.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%19.73%
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A
EBIT growth 1Y32.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year238.57%
EBIT Next 3Y159.98%
EBIT Next 5Y124.72%
FCF growth 1Y-304.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-405.01%
OCF growth 3YN/A
OCF growth 5YN/A